regulatory concerns

Nvidia posts $81.6B Q1 revenue beating expectations while Meta cuts 8,000 jobs and 6,000 open positions in restructuring.

Large-cap stocks in tech, EVs, and data centers fell 4.96%-18.28% amid weak guidance, rising yields, and competitive pressures.

Kissei Pharmaceutical urges caution on Tavneos use following FDA safety warnings and data integrity concerns, proposing withdrawal of the Amgen drug's approval.

Booking Holdings reports strong 2025 growth despite 16% stock decline, leveraging AI agents and expanding into alternative accommodations and airline bookings.

$VST drops 25% on regulatory fears but offers buying opportunity with nuclear assets, tech company PPAs, and Cogentrix acquisition fueling AI infrastructure growth.

Over 1,000 Hollywood creators urge regulators to block Paramount-Warner Bros merger, citing consolidation fears, while Paramount secures permanent financing reducing debt by $5 billion.

Apple avoids AI spending race while Microsoft, Meta, Google invest billions, instead incrementally integrating AI into existing products following its proven market-entry playbook.

Paramount Skydance secures $24B Gulf equity backing for Warner Bros. Discovery deal. Saudi PIF, Qatar QIA, and Abu Dhabi's L'imad hold non-voting stakes.

$TPB stock plunged 15.5% as FDA hesitation on nicotine pouch approvals threatens Fre brand growth, which rose 266% YoY but now faces regulatory headwinds.